Early screening of risk for multi-drug resistant organisms in the emergency department in patients with pneumonia and early septic shock: single-center, retrospective cohort study

CURRENT STATUS: UNDER REVIEW

Antimicrobial Resistance and Infection Control  ▪ BMC

Wen-Lin Su
Taipei Tzu Chi Hospital

I-Shiang Tzeng
Taipei Tzu Chi Hospital

Hao-Ai Shui
National Defense Medical Center

Meng-Yu Wu
Taipei Tzu Chi Hospital

Ming-Yieh Peng
Taipei Tzu Chi Hospital

Chih-Yu Chan
Taipei Tzu Chi Hospital

Edward D. Chan
National Jewish Health

Yao-Kuang Wu
Taipei Tzu Chi Hospital

Chou-Chin Lan
Taipei Tzu Chi Hospital

Mei-Chen Yang
Taipei Tzu Chi Hospital

Kuo-Liang Huang
Taipei Tzu Chi Hospital
Chih-Wei Wu  
Taipei Tzu Chi Hospital

Chia-Hui Chang  
Taipei Tzu Chi Hospital

Giou-Teng Yiang  
Taipei Tzu Chi Hospital

✉️ gtyiang@gmail.com  
Corresponding Author

ORCID: https://orcid.org/0000-0001-8473-3591

**DOI:**  
10.21203/rs.3.rs-20048/v1

**SUBJECT AREAS**  
General Microbiology  Infectious Diseases
Abstract

Background

Pneumonia is the fourth leading cause of death globally, with rapid progression during septic shock. Multidrug-resistant organisms (MDROs) are becoming more common with some healthcare-associated pneumonia events. Early detection of MDRO risk may improve the outcomes; however, the risk of MDROs in patients with pneumonia and septic shock is unknown and may need broad spectrum multidrug antibiotic therapy. This study investigated the disease outcomes and multidrug antibiotic therapy of pneumonia with early septic shock in patients admitted in the emergency department (ED), a population with a high prevalence of MDROs, after early screening of MDROs risk.

Methods

In this retrospective cohort study, patients with pneumonia and sepsis (n=533) admitted to the ED at the Taipei Tzu Chi Hospital from 2013 to 2019 were enrolled. The study population was divided into the high-risk and low-risk groups (patients from the communities or long-term care facilities with high and low prevalence of MDROs) and further divided into four subgroups to those whose screening procedure completed within 1 or 6 h of admission (high-risk within 1 h, high-risk within 6 h, low-risk within 1 h, and low risk within 6 h groups). The ICU mortality and multidrug antibiotic therapy were compared.

Results

The high-risk MDROs groups had higher percentage of P. aeruginosa than the low-risk group. Furthermore, the appropriate ED first antibiotics were higher in the “within 1 h” than in the “within 6 h” subgroup of the high-risk MDROs group. In multivariate analysis, the “within 6 h” high-risk MDROs subgroup had an adjusted odds ratio of 7.191 (95% CI: 2.911–17.767, p <0.001) and 2.917 (95% CI:1.456–5.847, p=0.003) for the ICU mortality and multidrug therapy in the ICU, respectively, after adjusting for other confounding factors.

Conclusions

Delayed MDRO screening in the high risk group had significant higher ICU mortality and multidrug antibiotic therapy in patients with pneumonia and early septic shock in the ED, especially in areas
with a high prevalence of MDROs.

Background

Pneumonia is the fourth leading cause of death in Taiwan and worldwide [1-5]. In 2016, the new U.S. guidelines for hospital acquired pneumonia were published, but they excluded healthcare-associated pneumonia (HCAP) because it had less-resistant pathogens [4]. However, in Taiwan 25.1–32% of HCAP cases were caused by virulent and drug-resistant pathogens, such as Pseudomonas aeruginosa [6-8]. As the national health insurance system in Taiwan is unique, HCAP was further divided into the respiratory care wards (RCW), hemodialysis-associated (HDAP), and nursing-home-associated pneumonia (NHAP), among patients in communities and long-term care facilities [3].

Several of the risk factors associated with infection with multidrug-resistant organisms (MDROs) were also elucidated in the guidelines for HCAP [9, 10]. Previous antibiotic exposure that exerts a selection pressure on bacteria is an important risk factor for MDROs and HCAP [11-13] Infections by MDROs are associated with initial inappropriate antibiotic therapy, increased length-of-stay in the hospital, and mortality [14, 15]. In Taiwan, the detection rate of MDROs in the long-term care facilities is 27.9-44.7% [16, 17], while the readmission rate within 1 month is 23.6% [18]. Thus, it is difficult for the emergency department (ED) physicians to choose the appropriate antibiotics for pneumonia immediately.

Sepsis is defined as a life-threatening organ dysfunction induced by systemic infection. Septic shock, which has a high mortality of approximately 38.5–51.7%, corresponds to sepsis with persisting hypotension requiring vasopressors and abnormal lactate levels despite adequate volume resuscitation [19, 20]. Therefore, broad spectrum antibiotics should be administered within 1 h when patients are suspected of having sepsis [21, 22]. Pneumonia with sepsis still had higher in-hospital mortality than other infections [23]. Therefore, broad spectrum antibiotics should be administered to patients with pneumonia-induced septic shock within 1 h in the ED.

The current 1-h sepsis bundles [24] and early antibiotics for pneumonia [25] increase the potential adverse effects associated with noncompliance, which can place a burden on the ED and the intensive care unit (ICU) critical care. There is still a lack of evidence for the net benefits of following the
treatment for septic shock and pneumonia with these regimens [24-26] In contrast, antibiotic multidrug or combination therapy was recommended to increase survival for patients with septic shock and mechanical ventilation by the Surviving Sepsis Campaign guidelines [21, 27-29] The impact of pneumonia with septic shock requiring broad spectrum antibiotics within 1 h of admission on ICU mortality and multidrug therapy remains unknown. We hypothesized that the prevalence of MDROs would be higher among patients with HCAP and septic shock than among those with community-acquired pneumonia (CAP). Early MDRO screening during ED admission may lead to the initial use of appropriate antibiotics and increase in the survival of patients with pneumonia with septic shock.

Materials And Methods

Study design and setting

This single-center, retrospective cohort study was approved by the Institutional Review Board of the Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation on August 20, 2019 (Protocol No.: 08-X-068) and was conducted in accordance with the guidelines of the amended Declaration of Helsinki. Waiver of informed consent was reviewed and approved by the Institutional Review Board, and patients’ data anonymity was protected. The study was performed in a facility settled within a 1000-bed tertiary referral hospital containing 45 medical intensive care unit (MICU) beds. The nurse-to-patient and respiratory therapist-to-patient ratios in the MICU were 1:2 and 1:10, respectively. Experienced physicians served all patients with pulmonary and critical care medicine issues, and in-hospital night coverage was provided by resident physicians. Consultation services were provided mostly by medical and surgical physicians.

Selection of Participants

This study enrolled patients with pneumonia and suspected septic shock, who were treated at the MICU of the Taipei Tzu Chi Hospital from July 1, 2013 to June 30, 2019. The ED electronic medical records were screened. Especially, the first three codes of the international classification of diseases (ICD)-9-CM codes 785.52, 995.91, 995.92, and the ICD-10-CM codes A41, R65.20, R65.21 were screened for sepsis and septic shock. Additionally, the ICD-9-CM codes 481 to 483, 485, 486, and the
ICD-10-CM codes J13 to J18 were screened for pneumonia.

Pneumonia classifications were based on risks of MDROs. HCAP was defined based on the patients' medical history of hospitalization for ≥2 days within 90 days prior to the diagnosis of infection or showing any of the following events within 30 days prior to the diagnosis of infection: attending to a healthcare institution, living in a nursing home (nursing home-associated pneumonia [NHAP]), or receiving medical treatments (wound care, chemotherapy, intravenous injections, or hemodialysis [HDAP]) [3, 30, 31]. CAP was defined based on the patients' history of not meeting any of the HCAP criteria. NHAP was further divided into the high-risk and low-risk groups (patients from the long-term care facilities with high and low prevalence of MDROs).

Screening of risks for the MDROs started from the time of the ED visit during the study periods. According to the MDROs risk phenotype classifications, pneumonia was further divided into the high-risk (high-risk HCAP and NHAP, and HDAP) and low-risk (low-risk NHAP and CAP) groups for the MDROs (Table 1) [9].

On July 1, 2016, the ED in the Taipei Tzu Chi Hospital advocated early screening of the MDROs and healthcare classifications for patients who were suspected of having sepsis, and changed the time of screening from 6 h to 1 h before taking the decision to administer antibiotics for the first time.

Patients with MDROs whose screening was completed within 6 h from July 1, 2013 to June 30, 2016 and those whose screening was completed within 1 h from July 1, 2016 to June 30, 2019, were enrolled. The “within 6 h” group was treated according to the 2005 US pneumonia treatment, 2007 Taiwan, and 2012 Surviving Sepsis Campaign (SSC) guidelines (Table 2) [27,32,33]. In contrast, the “within 1 h group” was treated based on the 2016 US, 2018 Taiwan, and 2016 SSC guidelines [3,4,21,34].

The study population was divided to four subgroups according to the MDROs risk phenotype, and the screening completion time within 1 or 6 h. The clinical outcomes were compared between these four groups (low-risk within 6 h, low-risk within 1 h, high-risk within 6 h, and high-risk within 1 h groups).

The inclusion criteria were symptoms of pneumonia and early sepsis encountered at the ED.

Pneumonia was defined as early onset of fever, cough, or phlegm, and infiltrations or patches in chest
X-ray. Patient had suspected septic shock and an ED physician decided whether fluid resuscitation or inotropes should be applied to keep the mean arterial pressure ≥ 65mmHg [19].

Patients who had infection (tuberculosis, viral, or fungal infections only), transferred from the RCW with nosocomial infections, could not admit to the ICU within 24 h, or those for whom hospice palliative care was decided were excluded from the study.

**Measurements**

Disease severity indexes of sepsis and pneumonia were collected from the ED or MICU including the pneumonia severity (CURB-65), acute physiology and chronic health evaluation II (APACHE II) [35], quick sequential organ failure assessment (qSOFA), and SOFA scores, and the mechanical ventilation and lactate levels. CURB-65 and qSOFA scores were measured as previously described [36]. Additionally, underlying comorbidities in patients were recorded and used to derive the Charlson comorbidity index (CCI) [37]. Previous antibiotic exposure was defined as at least one course of antibiotic therapy within 90 days before the current ED admission. Previous cultures were collected within 90 days of ED admission, where available.

CURB-65 was measured based on confusion (newly disoriented in person, place, or time), blood urea nitrogen (BUN) >20 mg/dl, respiratory rate ≥30 breaths/min, blood pressure (systolic [SBP]) <90 mmHg, or diastolic blood pressure ≤60 mmHg), and age ≥65 years [36] Additionally, underlying comorbidities (disabling neurologic conditions, chronic obstructive or restrictive lung disease, coronary atherosclerotic disease, congestive heart failure, liver cirrhosis, end-stage renal disease, diabetes, metastatic cancer, and acquired immunodeficiency syndrome) in patients were recorded. The comorbidities were used to derive the CCI [37]. The qSOFA score was calculated by adding one point for any of the following criteria: altered mental status (Glasgow coma scale <15), high respiratory rate (≥22/min), or low blood pressure (SBP ≤100 mmHg).

Sputum cultures were collected within 3 days of admission to the ED by expectoration, secretion suction, or endotracheal suction. The sputum quality was determined by the presence of squamous epithelial cells on Gram stain (≤10/low power field), and the first collection specimen with positive result and good quality was chosen.
Antimicrobial susceptibility test was performed according to the Clinical and Laboratory Standards Institute guidelines [13]. α- and β-streptococcus, and Haemophilus influenzae were subjected to the BBL™ Sensi-Disc™ susceptibility tests (Becton Dickinson and Company, Franklin Lakes, NJ, USA), and other bacteria were subjected to the minimum inhibitory concentration tests by using the VITEK®2 automated system (bioMérieux, Lyon, France). Antibiotic resistance was manually examined by the BBL Sensi-Disc test or automatically determined by the VITEK®2 automated system. Infection with polymicrobial pathogens in the sputum and more than two infection sources other than those developed in the lung, were recorded. MDROs were defined as vancomycin-resistant Enterococci, oxacillin-resistant Staphylococcus aureus, or multidrug-resistant Gram-negative bacilli (GNB), with acquired non-susceptibility to at least one agent in three or more antimicrobial categories [38].

The appropriate antibiotic treatment was defined as the final cultured microorganisms that were susceptible to the antibiotics used. Multidrug therapy was defined as a combined therapy of more than one antibiotic to broaden the antimicrobial coverage or accelerate pathogen clearance; this included combination therapies [21].

**Outcomes**

The clinical primary outcomes examined were the ICU and in-hospital mortality rates, length-of-stay in the ICU, and ventilator-use days. The secondary outcomes were the rates of the appropriate antibiotic treatment within 1 h and the rates of multidrug therapy in the ED and the ICU.

The initial admission time since the ED admission was measured. The ICU mortality was determined as the number of patients who died during the ICU admission divided by the total number of patients hospitalized. In-hospital mortality was determined as the number of patients who died during this admission divided by the total number of patients hospitalized. The length of the ICU stay was measured as the time from the ED admission to the end of the ICU care. Ventilator-use days were measured as the total number of days from the ED admission until the patient was weaned off the ventilators (including the non-invasive positive airway pressure and invasive mechanical ventilators).

**Statistical Analysis**

Continuous data are expressed as the mean ± standard deviation. Categorical data are expressed as
frequencies and percentages. The demographic and clinical characteristics were compared using the Student’s t-test between the “within 1 h” and “within 6 h” groups. The analysis of variance (ANOVA) was used for comparisons among the four subgroups. The chi-square test was used for comparing categorical variables between the subgroups. Additionally, we performed post-hoc analysis for continuous variables that showed significant differences. The Kaplan-Meier survival curve was used to examine mortality among different levels of risk for the MDROs. Multivariate analysis using the Cox regression analysis was performed to determine the factors associated with ICU mortality after adjusting for other confounding factors and those associated with multidrug therapy in the ICU. The data were analyzed using SPSS version 24.0 (IBM Corp, Armonk, NY, US) and a p-value of <0.05 was considered statistically significant.

Results

Characteristics of study participants

A total of 1,105 and 786 patients had initial shock only and pneumonia with shock, respectively, according to the ICD screening. According to the inclusion criteria of definite pneumonia with suspected initial septic shock by ED chart reviewed, a total of 542 patients participated. After the exclusion of nine patients who could not admit to the ICU within 24 h or had poor sputum quality, there were 533 patients were finally enrolled in this study. All patients were intubated with mechanical ventilation within 3 days from the ED admission. The total culture positive rate was 491/533 (92.1%) for the culture collected within 3 days from the initial ED admission with at least one culture availed by endotracheal suction, and 42/533 (7.9%) had mixed normal flora with good sputum quality. Of the 533 patients enrolled, 254 (48%) and 279 (52%) patients were screened within 1 h and 6 h for the risk of MDROs, respectively. The real MDROs protocol completion times that were retrospectively estimated for the “within 1 h” and “within 6 h” groups were 1.3±0.8 and 3.5±2.0 h, respectively (p <0.001) (Table 2). There was no difference in the protocol completion time between the low-risk and high-risk MDROs groups.

The baseline characteristics, underlying comorbidity, disease severity index, pneumonia classifications, previous infection experiences, and current infection events are shown in Table 2.
There were no significant differences in sex, age, underlying comorbidity, SOFA score, APACHE II score, lactate levels, ED mechanical ventilation, and infection experiences between the two groups. However, there was a higher disease severity with a qSOFA score of 3 (31.1% vs. 21.9%, p=0.018) and CURB-65 of 5 (29.1% vs. 20.1%, p=0.016), higher percentage of septic shock (40.6% vs. 29.0%, p=0.006), and higher percentage of polymicrobial infections (30.7% vs. 19.4%, p=0.003) in the “within 1 h” than in the “within 6 h” group.

**Laboratory data**

Comparisons of previous exposure to pathogens and antibiotic resistant phenotypes in the four subgroups stratified by the MDROs risks and the protocol completion time are shown in Table 3. Previous infection experiences and current infection events were significantly different between the four subgroups (p <0.001) apart from *K. pneumoniae*, the resistance phenotypes (aminoglycoside and ciprofloxacin), penicillin-resistant *Streptococcus pneumoniae*, and vancomycin-resistant *Enterococcus*. The culture positive rates were higher in the high than in the low MDROs risk subgroup especially those of *P. aeruginosa*, *A. baumannii*, and *S. aureus* (Table 3). *P. aeruginosa* (16.4% vs 18.9%), *K. pneumoniae* (12.3% vs 18.0%), *A. baumannii* (12.3% vs 18.0%), multidrug-resistant (MDR) GNB (30.5% vs 38.5%), and methicillin-resistant *S. aureus* (MRSA) (10.7% vs 10.9%) were more prevalent in the high-risk than in the low-risk groups (Table 3). After merging the data for the within 1 h and 6 h subgroups, the high-risk group had higher culture positive rates than the low-risk group for *P. aeruginosa* (25.6% vs. 9.5%, relative risk [RR] with confidence interval [CI]: 2.683 (1.769–4.069), p <0.001); *A. baumannii* (18.0% vs. 6.0%, RR (CI): 2.996 (1.761–5.098), p <0.001); and *S. aureus* (18.8% vs. 8.8%, RR (CI): 7.641 (2.711–21.536), p=0.001, Fisher’s exact test). Additionally, the drug-resistant phenotypes were significantly higher in the high-risk than in the low-risk subgroups including resistance to piperacillin/tazobactam, cefepime, carbapenem, MDR GNB, MRSA, and MDROs (Table 3).

After merging the data for the “within 1 h” and “within 6 h” groups, the high-risk group had significantly higher drug resistance phenotypes than the low-risk groups for piperacillin/tazobactam (10.8% vs. 2.5%, RR (CI): 4.366 (1.935–9.851), p <0.001); cefepime (9.2% vs. 1.8%, RR (CI): 5.207 (2.010–13.492), p <0.001); carbapenem (11.2% vs. 2.8%, RR (CI): 3.962 (1.840–8.532), p <0.001);
MDR GNB (34.4% vs. 0%, RR (CI): infinity, p <0.001); MRSA (10.8% vs. 1.4%, RR (CI): 7.641 (2.711–21.536), p <0.001); and MDROs (47.2% vs. 1.8%, RR (CI): 26.715 (11.097–64.316), p <0.001).

The MDRO prevalence was significantly higher in the groups at high-risk of MDROs (50.8% and 43.8% for the “within 1 h” and “within 6 h” subgroups, respectively) than in the groups at low risk (1.5% and 2.0% for the within 1 h and 6 h groups, respectively) (p <0.001). Moreover, the prevalence of previous antibiotic exposure was significantly higher in the high-risk groups (60.7% and 74.2% for the “within 1 h” and “within 6 h” subgroups, respectively) than in the low-risk subgroups (0%).

**Clinical outcomes data**

A total of 126 patients (23.6%) died in the ICU. Patients in the high-risk group had higher ICU and in-hospital mortalities than those in the low-risk group (Figure 1a and supplemental Figure 1). In the four subgroup comparisons, the RR (CI) of the ICU mortality in the “high-risk within 6 h,” “high-risk within 1 h,” and “low-risk within 6 h” groups compared with the “low-risk within 1 h” group, used as the reference group, were 3.094 (1.924-4.974), 2.359 (1.586-3.511), and 1.906 (1.291-2.815), respectively. For in-hospital mortality, the RR (CI) was 3.094 (2.013-4.755), 2.397 (1.673-3.436), and 1.937 (1.363-2.752), respectively. The patients in the “high-risk within 6 h” group had a longer length-of-stay in the ICU (14.4±13.1 vs. 10.9±8.9, p=0.008) and more ventilator use days (12.5±13.5 vs. 7.4±8.2, p<0.001) than those in the “low-risk within 1 h” group (Figure 1b). Antibiotic treatment was compared among the four groups. The patients in the high-risk group had a lower rate of appropriate antibiotic treatment in the ED (46.9% to 65.6% vs. 80.1% to 84.8%) and antibiotic checking in the ICU (65.6% to 67.2% vs. 82.8% to 84.8%) than those in the low-risk group (Figure 1c). Moreover, in the high-risk group, the rate of the appropriate antibiotic treatment in the ED was significantly lower in the “within 6 h” than in the “within 1 h” subgroup (6 h vs. 1 h: 46.9% vs. 65.6%, p=0.003).

The patients in the high-risk group had a higher percentage of multidrug therapy in the ED (10.9% to 15.6% vs. 0% to 11.3%) and ICU (23.8% to 41.4% vs. 11.4% to 17.9%) than those in the low-risk group. In the high-risk group, the multidrug therapy use was higher in the “within 1 h” than in the “within 6 h” group in the ED (15.6% vs. 10.9%, p=0.351 by Fisher’s exact test, Figure 1d), but
significantly lower in the “within 1 h” than in the “within 6 h” subgroup in the ICU (23.8% vs. 41.4%, p=0.003 by Fisher’s exact test, Figure 1d).

**Risk factors for the ICU mortality in pneumonia with sepsis at different screening time of MDROs**

The survival probabilities of the time from ED admission for the four subgroups are presented as Kaplan-Meier survival curves (Figure 2). The four subgroups had different levels of risks for MDROs on the day of ED admission (p < 0.001). The screening time (1 h vs. 6 h) had insignificant (p=0.434) and significant (p=0.002) effects on the survival curve in the low-risk and high-risk groups, respectively (Figure 2).

In the multivariable Cox regression analysis (Table 4), we found that patients in high-risk for MDROs (adjusted HR [aHR]=2.000, 95% CI: 1.153–3.470, p=0.014; CCI [aHR=1.325, 95% CI 1.231–1.428, p <0.001]; APACHE II [aHR=1.142, 95% CI: 1.106–1.180, p <0.001]; lactate levels [aHR=1.080, 95% CI: 1.023–1.139, p=0.005]; and septic shock [aHR=1.556, 95% CI: 1.065–2.272, p=0.022]) within 6 h of screening, had increased hazards of ICU mortality.

In the multivariate analysis adjusted for all the variables that had a p <0.05 in the univariate analysis (Table 5), the clinical features that were significantly associated with the ICU multidrug therapy included high-risk for MDROs within 6 h of screening (aOR=2.917, 95% CI: 1.456–5.847, p=0.003); CCI [aOR=1.126, 95% CI: 1.026–1.236, p=0.013]; APACHE II [aOR=1.065, 95% CI: 1.016–1.117, p=0.009]; and two sources of infection [aOR=2.411, 95% CI: 1.365–4.260, p=0.002]).

**Discussion**

Our study demonstrated that early screening (within 1 h) of the risk of MDROs increased the appropriateness of the ED first antibiotic use in patients with pneumonia and septic shock, and later, decreased the multidrug therapy in the ICU, and lowered the ICU mortality. The MDRO prevalence and previous antibiotic exposure were significantly higher in high-risk than in the low-risk groups of MDRO infection. Thus, MDROs persisted that records of previous cultures and hospitalization were important [39, 40] Screening for the HCAP criteria was beneficial in predicting drug-resistant pathogens, especially in patients with more than three HCAP risk factors [9]. Previous studies have reported
patients who were readmitted with previous antibiotic exposure within 90 days had multiple pathogens and drug-resistant bacteria at admission in Taiwan [41, 42] and worldwide [12, 43, 44]. There was a high prevalence of HCAP in Taiwan that required rapid differentiation for the selection of the appropriate antibiotics [6-8, 13] Here, especially in patients with pneumonia and sepsis, the prevalence rate of HCAP was 61.6–66.1% (Table 2). Furthermore, low-risk NHAP without previous antibiotic exposure emerged together with CAP as “low-risk for MDROs groups” and had very low MDROs and zero MDR GNB (Table 3). Therefore, MDROs risk screening is necessary and appropriate in areas with a high prevalence rate of HCAP.

In the Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) conference in 2016, HCAP was excluded from the hospital-acquired pneumonia/ventilator-associated pneumonia guidelines [4] because the HCAP criteria had low discriminatory ability for the MDROs [45-47] Furthermore, the clinical outcomes in HCAP were similar in severity as that in CAP, despite the initial inappropriate antibiotic therapy, in some studies [45, 48] In contrast, MDROs risk screening including previous antibiotic exposure or admissions within 90 days in nursing homes, with high prevalence of MDROs, was more important than the HCAP criteria, which only determine the possibility of MDROs pathogens, such as the drug-resistant P. aeruginosa and MRSA [9, 11, 46]. P. aeruginosa, K. pneumoniae, A. baumannii, MDR GNB, and MRSA were more prevalent in the high-risk than in the low-risk groups. Therefore, multidrug therapy was necessary and appropriate, as mentioned in the new guideline for pneumonia [3, 4]. In 2019, the ATS/IDSA guidelines recommended that the HCAP category should no longer be used [5]. However, the guideline emphasized the relevance of the local epidemiology and validated the risk factors including recent hospitalization and prior respiratory isolation to determine the need for MRSA and P. aeruginosa coverage. Here, the high-risk groups were classified with previous antibiotic exposure (60.7–74.2%) and culture results (64.8–77.3%) (Table 3). Moreover, the high-risk groups had 30.5–38.5% MDR GNB and 10.7–10.9% MRSA. This suggests that the MDROs risk screening is suitable for drug-resistant classification in patients with pneumonia and sepsis and could ensure that they received immediate and appropriate antibiotic therapy in the ED (Fig. 1c).
Unidentified pneumonia with sepsis at the ED delays the appropriate antibiotic therapy [49]. Initial inappropriate antibiotic treatment increases mortality and delays the resolution of pneumonia [50, 51]. Furthermore, the timing of appropriate antibiotics is important for the treatment of sepsis and septic shock and improves the length of the ICU stay and in-hospital mortality [52–54]. Broad-spectrum empiric antibiotic treatment within 1 h is the standard procedure for patients with suspected sepsis at the ED triage [22, 55]. In the groups at high risk of infection with MDROs, the proportion of patients who received appropriate antibiotics in the ED was significantly higher in the “within 1 h” than in the “within 6 h” group, but there was no significant difference between the “within 1 h and 6 h” groups in the proportion who received appropriate antibiotics in the ICU. This suggests that early MDRO-risk screening is important because it provides immediate information on the probability of infection with MDROs.

Late administration of the appropriate antibiotics in the ED occurs due to undetermined infection. For each hour of delay of antibiotic administration, there is a 12% reduction in survival of patients with sepsis [52]. Furthermore, an increase in the time for the appropriate antibiotic therapy prolongs the ICU stay [54]. High prevalence of MDROs often occurs in the long-term care facilities due to repeated admissions in the Taiwan hospital systems [16, 18] Here, in the high-risk for MDROs group, there was lower appropriate initial antibiotics use in the ED in the “within 6 h” than in the “within 1 h” screening subgroup (46.9% vs. 65.6%, p = 0.003, Fig. 1d). Especially the “within 6 h” screening subgroup had the longest length of ICU stay (14.4 days) and ventilator use days (12.5 days) (Fig. 1d). After adjusting for other confounding factors, high-risk for the MDROs within 6 h screening was an independent risk factor for ICU mortality (aHR = 2.000, p = 0.014, Table 4).

Multidrug (combination) therapy is necessary for severe in-patient pneumonia according to the 2019 ATS/IDSA CAP guidelines and includes beta-lactams combined with macrolide or fluoroquinolone [5]. In the groups at low-risk of infections with MDROs, those in the “within 1 h and 6 h” subgroups had similar probability of receiving multidrug therapy in the ICU (Fig. 1d). This suggests that early screening for MDROs does not increase the probability of multidrug therapy in the low-risk groups in the ICU. Furthermore, at the high risk for MDROs group, the multidrug therapy was lower in the
“within 1 h” than in the “within 6 h” subgroup (Fig. 1d). In the logistic regression model, the high-risk for MDROs within 6 h screening subgroup had significantly higher correlation with multidrug therapy than with other groups in the ICU (p = 0.003, Table 5). Thus, we concluded that the 1 h protocol completion would not increase the multidrug therapy use in the ICU antibiotic selection. Global awareness of sepsis and antimicrobial stewardship should be considered as a two-sided coin [56, 57]. ED and critical care physicians who use broad spectrum and multidrug therapy within 1 h are committed to survival of patients with sepsis and are undertaking the global responsibility to prevent rapid antimicrobial resistance. Early MDROs screening within 1 h for patients with pneumonia and sepsis may ensure appropriate selection of broad-spectrum multidrug therapy in the ED and later, and possible decrease the multidrug therapy use in the ICU in our study.

Although multidrug (combination) therapy is recommended especially in patients with septic shock, early discontinuation was suggested when culture results become available and/or clinical outcomes are stabilized to prevent the development of drug-resistant pathogens due to selection pressure [21]. Here, in the high-risk for MDROs groups, the antibiotic multidrug therapy was higher in the “within 1 h” than in the “within 6 h” subgroup in the ED, but significantly lower in the ICU. We conclude that the initial use of multidrug therapy in the ED guided by MDROs risk screening did not further increase the applied multidrug therapy in the ICU. Furthermore, ED multidrug therapy use did not affect ICU mortality (Table 4 and Table 5). These results suggest that early MDROs risk screening is suitable for practical application.

In conclusion, MDROs screening within 6 h in patients with pneumonia and early septic shock in high-risk for MDROs is an independent risk factor for ICU mortality since it is related to inappropriate initial antibiotics use in the ED and higher rate of multidrug therapy in the ICU. However, further prospective studies are needed to be performed with randomized comparisons of MDROs screening within 1 and 6 h of ED admission, especially in areas with a high prevalence of MDROs.

Limitations
There were some study limitations. This was a retrospective study with two MDRO risk screening policies in the ED. The 1-h completion policy might have increased the appropriate antibiotic use in
the ED and later lower the ICU mortality in the high risk MDRO subgroups, but this study design still involves selection bias. There were two reasons as follows: first, as the MDRO risk screening policy regarding the sepsis definition was changed in July 2016, the pneumonia treatment guidelines were also changed and the good clinical outcomes may be related to the changes in MDRO screening and treatment improvements; second, shock status and lactate level data collected for making a diagnosis of pneumonia with septic shock were not easy to be complete in the within 1 h screening. These biases could mean that the conclusion only applied to the early onset of pneumonia with septic shock. The data of late onset of pneumonia with septic shock, which were confirmed after 1 h of ED admission, were still missed in this study.

Abbreviations

HCAP, healthcare-associated pneumonia; RCW, respiratory care wards; HDAP, hemodialysis-associated pneumonia; NHAP, nursing-home-associated pneumonia; MDROs, multidrug-resistant organisms; ED, emergency department; ICU, intensive care unit; CAP, community-acquired pneumonia; MICU, medical intensive care unit; SSC, Surviving Sepsis Campaign; APACHE II, acute physiology and chronic health evaluation II; qSOFA, quick sequential organ failure assessment; CCI, Charlson comorbidity index; BUN, blood urea nitrogen; MDR, multidrug-resistant, GNB, gram-negative bacilli; MRSA, methicillin-resistant S. aureus; RR, relative risk; CI, confidence interval; IDSA, Infectious Diseases Society of America

Declarations

Ethics approval and consent to participate

This single-center, retrospective cohort study was approved by the Institutional Review Board of the Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, and New Taipei City, Taiwan on August 20, 2019 (Protocol No.: 08-X-068) and was conducted in accordance with the guidelines of the amended Declaration of Helsinki.

Consent for publication

For this retrospective cohort study, the informed consent waiver was received from IRB and the patient privacy rights including any individual person’s data in any form (including individual details,
images or videos) are observed. This study was approved by the Institutional Review Board of Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (approval number 08-X-068) and conducted in accordance with the amended Declaration of Helsinki.

**Availability of data and materials**

The data that support the findings of this study are available from Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by grants from the Taipei Tzu Chi Hospital [TCRD-TPE-107-38] and Buddhist Tzu Chi Medical Foundation [TCMF-A 109-05 (109)].

**Authors contributions**

WLS, GTY conceived the study, designed the trial, and obtained research funding. WLS, HAS, MYP supervised the conduct of the trial, data collection, and critical revision. WLS, IST, HAS, MYW provided statistical advice on study design and analyzed the data; MYW, CYC, EDC, YKW, CCL, MCY, KLH, CWW, CHC provided data analysis, data interpretation, and manuscript preparation. WLS, GTY chaired the data oversight committee. WLS drafted the manuscript, and all authors contributed substantially to its revision. GTY takes responsibility for the paper as a whole.

**Acknowledgements**

We would like to thank Editage (www.editage.com) for English language editing and Publication Support.

**References**

1. Ministry of Health and Welfare. The News Press of Ministry of Health and Welfare. Theme: Taiwan’s Leading Causes of Death in 2017.
http://www.cdway.com.tw/gov/mhw2/book107/book1e/. Accessed 8 May 2019

2. World Health Organization. Top 10 causes of death in Global Health Observatory (GHO) data between 2000 to 2016. In: Global Health Observatory (GHO) data. https://www.who.int/gho/mortality_burden_disease/causes_death/top_10/en

3. Chou CC, Shen CF, Chen SJ, Chen HM, Wang YC, Chang WS, et al. Recommendations and guidelines for the treatment of pneumonia in Taiwan. J Microbiol Immunol Infect. 2019;52:172–99.

4. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–e111.

5. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45–67.

6. Wu CL, Ku SC, Yang KY, Fang WF, Tu CY, Chen CW, et al. Antimicrobial drug-resistant microbes associated with hospitalized community-acquired and healthcare-associated pneumonia: a multi-center study in Taiwan. J Formos Med Assoc. 2013;112:31–40.

7. Wang PH, Wang HC. Risk factors to predict drug-resistant pathogens in hemodialysis-associated pneumonia. BMC Infect Dis. 2016;16:377.

8. Fang WF, Yang KY, Wu CL, Yu CJ, Chen e-associated pneumonia. Crit Care. 2011;15:R32.

9. Webb BJ, Dangerfield BS, Pasha JS, Agrwal N, Vikram HR. Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. Respir Med. 2012;106:1606-12.
10. Mascitti H, Duran C, Nemo E-M, Bouchand F, Câlin R, Descatha A, Gaillard J-L, Lawrence C, Davido B, Barbier F et al: Factors associated with bacteraemia due to multidrug-resistant organisms among bacteraemic patients with multidrug-resistant organism carriage: a case control study. Antimicrobial Resistance & Infection Control 2018; 7(1):116.

11. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010;340:c2096.

12. Kuster SP, Rudnick W, Shigayeva A, Green K, Baqi M, Gold WL, et al. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. Clin Infect Dis. 2014;59:944–52.

13. Su WL, Shui HA, Peng MY: Ignorance of pre-ED healthcare setting is a factor leading to inappropriate initial antibiotic treatment of sepsis in ED and poor outcomes in ICU. J Microbiol Immunol Infect 2019. DOI: 1016/j.jmii.2019.11.001

14. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH, et al. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18:596.

15. Barrasa-Villar JL, Aibar-Remon C, Prieto-Andres P, Mareca-Donate R, Moliner-Lahoz J,. Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms. Clin Infect Dis. 2017;65:644–52.

16. Lee CM, Lai CC, Chiang HT, Lu MC, Wang LF, Tsai TL, et al. Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan. J Microbiol Immunol Infect. 2017;50:133–44.

17. Lin IW, Huang C-Y, Pan S-C, Chen Y-C, Li C-M: Duration of colonization with and risk factors for prolonged carriage of multidrug resistant organisms among residents in
long-term care facilities. Antimicrobial Resistance & Infection Control 2017, 6(1):86.

18. Garcia-Perez L, Linertova R, Lorenzo-Riera A, Lu MC, Wang LF, Tsai TL. Risk factors for hospital readmissions in elderly patients: a systematic review. 2011;104:639–51.

19. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.

20. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:775–87.

21. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45:486–552.

22. Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Crit Care Med. 2018;46:997–1000.

23. Song DH, Chae MK, Hwang SY, Jin SC, Lee TR, Cha WC, et al. Impact of source of infection on outcome in patients with severe sepsis and septic shock in the emergency department. Ann Emerg Med. 2014;64:S18.

24. Spiegel R, Farkas JD, Rola P, Kenny JE, Oluasanya S, Marik PE, et al. The 2018 surviving sepsis campaign’s treatment bundle: when guidelines outpace the evidence supporting their use. Ann Emerg Med. 2019;73:356–8.

25. Pines JM. Measuring antibiotic timing for pneumonia in the emergency department: another nail in the coffin. Ann Emerg Med. 2007;49:561–3.

26. Talan DA, Yealy DM. Challenging the one-h bundle goal for sepsis antibiotics. Ann Emerg Med. 2019;73:359–62.
27. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580-637.

28. Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010;54:1742-48.

29. Capsoni N, Bellone P, Aliberti S, Sotgiu G, Pavanello D, Visintin B, Callisto E, Saderi L, Soldini D, Lardera L et al: Prevalence, risk factors and outcomes of patients coming from the community with sepsis due to multidrug resistant bacteria. Multidiscip Respir Med 2019, 14:23.

30. Cardoso T, Almeida M, Friedman ND, Aragao I, Costa-Pereira A, Sarmento AE, et al. Classification of healthcare-associated infection: a systematic review 10 years after the first proposal. BMC Med. 2014;12:40.

31. Micek ST, Kollef KE, Reichley RM, Roubian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568-73.

32. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.

33. Infectious Diseases Society of Taiwan, Taiwan Society of Pulmonary and Critical Medicine, Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines Guidelines on antimicrobial therapy of pneumonia in adults in Taiwan, revised 2006. J Microbiol
34. Kumar ST, Yassin A, Bhowmick T, Dixit D. Recommendations from the 2016 guidelines for the management of adults with hospital-acquired or ventilator-associated pneumonia. P T. 2017;42:767-72.

35. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-29.

36. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. 2003;58:377-82.

37. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.

38. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.

39. Bolten BC, Bradford JL, White BN, Heath GW, Sizemore JM, White CE: Effects of an automatic discontinuation of antibiotics policy: A novel approach to antimicrobial stewardship. Am J Health Syst Pharm 2019, 76(Supplement_3):S85-S90.

40. Ma X, Wu Y, Li L, Xu Q, Hu B, Ni Y, Wu A, Sun S, Jarlier V, Robert J: First multicenter study on multidrug resistant bacteria carriage in Chinese ICUs. BMC Infect Dis 2015, 15:358.

41. Ting SW, Lee CH, Liu JW. Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: a retrospective propensity-matched case control study. J Microbiol Immunol Infect. 2018;51:621-8.
42. Tsao LH, Hsin CY, Liu HY, Chuang HC, Chen LY, Lee YJ, et al. Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa. J Microbiol Immunol Infect. 2018;51:359–66.

43. Johnson MT, Reichley R, Hoppe-Bauer J, Dunne WM, Micek S, Kollef M. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med. 2011;39:1859–65.

44. Hui C, Lin MC, Jao MS, Liu TC, Wu RG. Previous antibiotic exposure and evolution of antibiotic resistance in mechanically ventilated patients with nosocomial infections. J Crit Care. 2013;28:728–34.

45. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis. 2014;58:330–9.

46. Gross AE, Van Schooneveld TC, Olsen KM, Rupp ME, Bui TH, Forsung E. et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother. 2014;58:5262–8.

47. Yap V, Datta D, Metersky ML. Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens? Infect Dis Clin North Am. 2013;27:1–18.

48. Valles J, Martin-Loeches I, Torres A, Diaz E, Seijas I, Lopez MJ, et al. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med. 2014;40:572–81.

49. Cullen M, Fogg T, Delaney A. Timing of appropriate antibiotics in patients with septic shock: a retrospective cohort study. Emerg Med Australas. 2013;25:308–15.

50. Moehring RW, Sloane R, Chen LF, Smathers EC, Schmader KE, Fowler VG, et al. Delays in appropriate antibiotic therapy for gram-negative bloodstream infections: a
multicenter, community hospital study. PLoS One. 2013;8:e76225.

51. Li M, Liu J, Tan R, Liu Z, Yin J, Qu H. Risk factors for slowly resolving pneumonia in the intensive care unit. J Microbiol Immunol Infect. 2016;49:654–62.

52. Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first h: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:1749–55.

53. Seymour CW, Gesten F, Prescott HC, Iwashyna TJ, Phillips GS, Lemeshow S, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med. 2017;376:2235–44.

54. Zhang D, Micek ST, Kollef MH. Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis. Crit Care Med. 2015;43:2133–40.

55. Sherwin R, Winters ME, Vilke GM, Wardi G. Does early and appropriate antibiotic administration improve mortality in emergency department patients with severe sepsis or septic shock? J Emerg Med. 2017;53:588–95.

56. Fitzpatrick F, Tarrant C, Hamilton V, Kiernan FM, Jenkins D, Krockow EM. Sepsis and antimicrobial stewardship: two sides of the same coin. BMJ Qual Saf. 2019;28:758–61.

57. Ma X, Xie J, Yang Y, Guo F, Gao Z, Shao H, Huang Y, Yang C, Qiu H: Antimicrobial stewardship of Chinese ministry of health reduces multidrug-resistant organism isolates in critically ill patients: a pre-post study from a single center. BMC Infect Dis 2016, 16(1):704.

Tables

Table 1. Screening and antibiotic treatment of risk for MDROs for pneumonia with septic shock
MDROs, multidrug-resistant organisms; CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; HCAP, healthcare-associated pneumonia;

Table 2: Demographic characteristics of patients stratified by the protocol completion time

|                           | Within 1 h     | Within 6 h     |
|---------------------------|----------------|----------------|
| **Estimated time, h (Mean ± SD)** | 1.3 ± 0.8 (1)  | 3.5 ± 2.0 (3)  |
| Low risk for MDROs        | 1.3 ± 0.8 (1)  | 3.5 ± 2.0 (3)  |
| High risk for MDROs       | 1.4 ± 0.8 (1)  | 3.6 ± 2.1 (3)  |
| **Sex**                   |                |                |
| Female                    | 100 (39.4%)    | 122 (43.7%)    |
| Male                      | 154 (60.6%)    | 157 (56.3%)    |
| **Ages**                  | 76.3 ± 12.3    | 76.0 ± 13.5    |
| **Charlson comorbidity index** | 6.8 ± 2.8     | 6.5 ± 3.0      |
| **Disease severity index** |                |                |
| qSOFA                     | 2              |                |
| 2                         | 175 (68.9%)    | 218 (78.1%)    |
| CURB-65 |       |       |
|---------|-------|-------|
| 3       | 79 (31.1%) | 61 (21.9%) |
| 4       | 180 (70.9%) | 223 (79.9%) |
| 5       | 74 (29.1%) | 56 (20.1%) |
| **SOFA score** | **9.3 ± 2.7** | **9.4 ± 3.2** |
| **APACHE II** | **27.2 ± 5.8** | **26.4 ± 6.1** |
| **Lactate (mmol/l)** | **2.8 ± 2.6** | **2.4 ± 2.5** |
| **Mechanical ventilation** | 165 (65.0%) | 190 (68.1%) |

**ED Oxygenation (ventilation)**

| Non-rebreathing mask | 89 (31.9%) | 89 (31.9%) |
| Noninvasive ventilation | 32 (12.6%) | 45 (16.1%) |
| Invasive ventilation | 133 (52.4%) | 145 (52.0%) |

**Pneumonia classification**

| CAP | 86 (33.9%) | 107 (38.4%) |
| Low risk NHAP | 46 (18.1%) | 44 (15.8%) |
| HDAP | 24 (9.4%) | 32 (11.5%) |
| High risk NHAP | 36 (14.2%) | 21 (7.5%) |
| High risk HCAP | 62 (24.4%) | 75 (26.9%) |

**MDRO risk phenotype**

| Low risk MDRO | 132 (52.0%) | 151 (54.1%) |
| High risk MDRO | 122 (48.0%) | 128 (45.9%) |

**Previous infection experience**

| Previous antibiotic exposure | 74 (29.1%) | 95 (34.1%) |
| Previous culture available | 79 (31.1%) | 99 (35.5%) |

**Infection events**

| Polymicrobial infection | 78 (30.7%) | 54 (19.4%) |
| More than 2 infection sources | 66 (26.0%) | 65 (23.3%) |
| MDROs | 64 (25.2%) | 59 (21.1%) |

qSOFA, quick Sepsis-related Organ Failure Assessment; APACHE II, Acute Physiology and Chronic
Health Evaluation II; MDRO, multidrug-resistant organisms; HCAP, healthcare-associated pneumonia; CAP, community-acquired pneumonia; NHAP, nursing home associated pneumonia; HDAP, hemodialysis associated pneumonia; SD, standard deviation.

(*) Statistical significant (p <0.05)

Table 3: Comparison of previous exposure to pathogens and antibiotic-resistant phenotypes in the four subgroups stratified by MDROs risks and protocol completion time

| MDROs risks | Low risk | Low risk | High risk |
|-------------|----------|----------|-----------|
| Protocol completion time | within 1 h | within 6 h | within 1 h |
| (N=132) | (N=151) | (N=122) |

Previous infection experience

| Previous antibiotics | 0 (0%) | 0 (0%) | 74 (60.7%) |
| Previous cultures | 0 (0%) | 0 (0%) | 79 (64.8%) |

Infection events

| Polymicrobial | 18 (13.6%) | 10 (6.6%) | 60 (49.2%) |
| More than 2 sources | 28 (21.2%) | 18 (11.9%) | 38 (31.1%) |

Pathogens

| P. aeruginosa | 12 (9.1%) | 15 (9.9%) | 34 (27.9%) |
| K. pneumoniae | 18 (13.6%) | 21 (13.9%) | 28 (23.0%) |
| A. baumanni | 9 (6.8%) | 8 (5.3%) | 22 (18.0%) |
| S. aureus | 13 (9.8%) | 12 (8.0%) | 23 (18.8%) |
| S. pneumoniae | 19 (14.4%) | 25 (16.6%) | 4 (3.3%) |

Resistance phenotype
Table 4: Cox regression model after adjusting for other confounding factors

|                      | Bivariate       | Multivariate   |
|----------------------|-----------------|----------------|
|                      | HR (95% CI)     | p-value        | HR (95% CI)     | p-value        |
| Protocol MDROs       | Ref:1 (1 h low) | < 0.001*       | 0.013*          |
| 2 (6 h low)          | 1.300 (0.716– 2.361) | 0.389          | 1.609 (0.883– 2.933) | 0.120          |

VRE, Vancomycin-resistant Enterococcus; GNB, Gram-negative bacilli; PRSP, Penicillin-resistant Streptococcus pneumoniae; MDR, Multidrug-resistant; MRSA, Methicillin-resistant S. aureus; MDRO, multidrug-resistant organisms; Pathogens, the most popular five pathogens were selected.

(*) Statistical significant (p <0.05)
| Variable            | Coefficient | 95% CI         | p-value |
|---------------------|-------------|----------------|---------|
| 3 (1 h high)        | 1.589       | (0.875–2.885)  | 0.128   |
|                     | 1.037       | (0.567–1.899)  | 0.318   |
| 4 (6 h high)        | 3.234       | (<0.001*)      | 0.014*  |
|                     | 2.000       | (1.153–3.470)  |         |
| Age                 | 1.007       | (0.993–1.022)  | 0.958   |
|                     | 1.022       | (0.672–1.366)  | 1.318   |
| Sex                 | 0.958       | (0.672–1.366)  | 0.958   |
|                     | 0.812       | (1.153–1.366)  | 1.318   |
| CCI                 | 1.293       | (<0.001*)      | 0.014*  |
|                     | 1.325       | (1.231–1.428)  |         |
| qSOFA               | 1.893       | (<0.001*)      | 0.258   |
|                     | 2.000       | (1.153–3.470)  |         |
| CURB65              | 1.920       | (<0.001*)      | 0.201   |
|                     | 2.000       | (1.153–3.470)  |         |
| SOFA score          | 1.168       | (<0.001*)      | 0.211   |
|                     | 1.007       | (0.993–1.022)  | 0.958   |
| APACHE II           | 1.167       | (<0.001*)      | 0.014*  |
|                     | 1.142       | (1.106–1.180)  |         |
| Lactate             | 1.109       | (<0.001*)      | 0.005*  |
|                     | 1.080       | (1.023–1.139)  |         |
| Ventilator use      | 2.118       | (<0.001*)      | 0.222   |
|                     | 3.000       | (1.153–3.470)  |         |
| Variable                        | Univariate | Multivariate |
|--------------------------------|------------|--------------|
| Previous culture               | 1.844 (1.300–2.616) | 0.444        |
| Polymicrobial                   | 1.650 (1.148–2.371) | 0.643        |
| Two sources of infection        | 1.549 (1.072–2.239) | 0.283        |
| MDRO                            | 1.377 (0.943–2.011) | 0.097        |
| ED first antibiotics            | 2.564 (1.807–3.639) | <0.001*      |
| ED broad spectrum               | 1.194 (0.658–2.167) | 0.560        |

Events: ICU mortality, time: days since ED admission to discharge or in-hospital mortality

Selection: stepwise

HR, hazard ratio; CI, confidence interval; MDROs, multidrug-resistant organisms; CCI, Charlson comorbidity index; qSOFA, quick sepsis-related organ failure assessment; APACHE II, Acute Physiology and Chronic Health Evaluation II; ED, emergency department.

(*) Statistical significant (p <0.05)

Table 5: Logistic regression model after adjusting for other confounding factors
| Protocol MDRO | Ref:1(1 h low) | <0.001* | OR (95% CI) | p-value | OR (95% CI) | p-value |
|---------------|----------------|---------|-------------|---------|-------------|---------|
| 2 (6 h low)   | 1.698 (0.861–3.352) | 0.127 | 0.789 (0.332–1.875) | 0.591 | 0.789 (0.332–1.875) | 0.591 |
| 3 (1 h high)  | 2.432 (1.232–4.802) | 0.010* | 0.619 (0.258–1.484) | 0.282 | 0.619 (0.258–1.484) | 0.282 |
| 4 (6 h high)  | 5.512 (2.900–10.478) | <0.001* | 2.917 (1.456–5.847) | 0.003* | 2.917 (1.456–5.847) | 0.003* |
| Sex           | 0.985 (0.655–1.480) | 0.942 | 1.480 | | 1.480 |
| Age           | 1.009 (0.993–1.025) | 0.277 | | 1.025 | | 1.025 |
| CCI           | 1.118 (1.043–1.199) | 0.002* | 1.126 (1.026–1.236) | 0.013* | 1.126 (1.026–1.236) | 0.013* |
| qSOFA         | 1.547 (0.999–2.395) | 0.051 | | | 1.547 (0.999–2.395) | 0.051 |
| CURB-65       | 1.445 (0.922–2.264) | 0.108 | | | 1.445 (0.922–2.264) | 0.108 |
| SOFA score    | 1.143 (1.069–1.223) | <0.001* | | 0.330 | 1.143 (1.069–1.223) | <0.001* |
| APACHE II     | 1.099 (1.061–1.139) | <0.001* | 1.065 (1.016–1.096) | 0.009* | 1.065 (1.016–1.096) | 0.009* |
|               |                      |        |              |         |              |         |
| Variable                  | OR     | CI         | p-value |
|--------------------------|--------|------------|---------|
| Lactate                  | 1.020  | (0.946–1.099) | 0.608   |
| Ventilator use           | 1.178  | (0.764–1.816) | 0.459   |
| Previous culture         | 2.025  | (1.341–3.058) | 0.001*  | 0.395 |
| Polymicrobial             | 2.327  | (1.507–3.592) | <0.001* | 0.160 |
| Two sources of infection  | 2.139  | (1.383–3.310) | 0.001*  | 2.411 (1.365–4.260) | 0.002* |
| ED antibiotics            | 1.754  | (1.151–2.672) | 0.009*  | 0.103 |
| ED broad spectrum         |        |            | 0.997   |

**Dependent variable:** ICU multidrug therapy

OR, odds ratio; CI, confidence interval; MDROs, multi-drug resistant organisms; CCI, Charlson comorbidity index; qSOFA, quick sepsis-related organ failure assessment; APACHE II, Acute Physiology and Chronic Health Evaluation II; ED, emergency department.

(*) Statistical significant (p <0.05)

**Supplemental Information Note**
The supplemental figure mentioned on page 14 was omitted by the authors in this version of the
paper.

Figures
Figure 1

Bar charts showing the significant differences. The proportions of (a) mortality, (b) stay length in ICU and ventilator use days, (n) inappropriate rate of antibiotics, and (d) multidrug antibiotic rate between four subgroups stratified by the MDROs risks and protocol completion times are presented. The overall probability values (p values) calculated by the Chi square or Fisher’s exact test are shown at the top of charts. The stay length in the ICU and the ventilator use days were calculated by the one-way ANOVA and Post hoc pairwise least significant difference tests. (*), (**), and (***) indicate p <0.05, <0.01, and <0.001 for significance difference of the paired bars, respectively. MDROs, multidrug-resistant organisms; ICU, intensive care unit; ED, emergency department.
Survival curves according to different risks for MDROs, and protocol completion times (four groups). The Kaplan-Meier survival analysis was undertaken in the data of patients with (a) low-risk for MDROs within 1 h of screening, (b) low-risk for MDROs within 6 h of screening, (c) high-risk for MDROs within 1 h of screening, and (d) high-risk for MDROs within 6 h of screening during their entire hospital stay. Log-rank test: p <0.001; low risk for MDROs: 6 h vs. 1 h, p=0.434; high risk for MDROs: 6 h vs. 1 h, p=0.002 MDROs, multidrug-resistant organisms.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
